136 related articles for article (PubMed ID: 38720086)
1. Computationally restoring the potency of a clinical antibody against Omicron.
Desautels TA; Arrildt KT; Zemla AT; Lau EY; Zhu F; Ricci D; Cronin S; Zost SJ; Binshtein E; Scheaffer SM; Dadonaite B; Petersen BK; Engdahl TB; Chen E; Handal LS; Hall L; Goforth JW; Vashchenko D; Nguyen S; Weilhammer DR; Lo JK; Rubinfeld B; Saada EA; Weisenberger T; Lee TH; Whitener B; Case JB; Ladd A; Silva MS; Haluska RM; Grzesiak EA; Earnhart CG; Hopkins S; Bates TW; Thackray LB; Segelke BW; ; Lillo AM; Sundaram S; Bloom JD; Diamond MS; Crowe JE; Carnahan RH; Faissol DM
Nature; 2024 May; 629(8013):878-885. PubMed ID: 38720086
[TBL] [Abstract][Full Text] [Related]
2. Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants.
Desautels TA; Arrildt KT; Zemla AT; Lau EY; Zhu F; Ricci D; Cronin S; Zost SJ; Binshtein E; Scheaffer SM; Dadonaite B; Petersen BK; Engdahl TB; Chen E; Handal LS; Hall L; Goforth JW; Vashchenko D; Nguyen S; Weilhammer DR; Lo JK; Rubinfeld B; Saada EA; Weisenberger T; Lee TH; Whitener B; Case JB; Ladd A; Silva MS; Haluska RM; Grzesiak EA; Earnhart CG; Hopkins S; Bates TW; Thackray LB; Segelke BW; Lillo AM; Sundaram S; Bloom J; Diamond MS; Crowe JE; Carnahan RH; Faissol DM
bioRxiv; 2023 Apr; ():. PubMed ID: 36324800
[TBL] [Abstract][Full Text] [Related]
3. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
[TBL] [Abstract][Full Text] [Related]
4. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
Cameroni E; Bowen JE; Rosen LE; Saliba C; Zepeda SK; Culap K; Pinto D; VanBlargan LA; De Marco A; di Iulio J; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà PE; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Snell G; Veesler D; Corti D
Nature; 2022 Feb; 602(7898):664-670. PubMed ID: 35016195
[TBL] [Abstract][Full Text] [Related]
5. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.
Wang Q; Guo Y; Iketani S; Nair MS; Li Z; Mohri H; Wang M; Yu J; Bowen AD; Chang JY; Shah JG; Nguyen N; Chen Z; Meyers K; Yin MT; Sobieszczyk ME; Sheng Z; Huang Y; Liu L; Ho DD
Nature; 2022 Aug; 608(7923):603-608. PubMed ID: 35790190
[TBL] [Abstract][Full Text] [Related]
6. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution.
Cao Y; Jian F; Wang J; Yu Y; Song W; Yisimayi A; Wang J; An R; Chen X; Zhang N; Wang Y; Wang P; Zhao L; Sun H; Yu L; Yang S; Niu X; Xiao T; Gu Q; Shao F; Hao X; Xu Y; Jin R; Shen Z; Wang Y; Xie XS
Nature; 2023 Feb; 614(7948):521-529. PubMed ID: 36535326
[TBL] [Abstract][Full Text] [Related]
7. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
8. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
[TBL] [Abstract][Full Text] [Related]
9. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
[TBL] [Abstract][Full Text] [Related]
10. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.
Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y
J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Optimization of One Neutralizing Antibody against SARS-CoV-2 Variants Bearing the L452R Mutation.
Chen Y; Zha J; Xu S; Shao J; Liu X; Li D; Zhang X
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675908
[TBL] [Abstract][Full Text] [Related]
12. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies.
Sheward DJ; Pushparaj P; Das H; Greaney AJ; Kim C; Kim S; Hanke L; Hyllner E; Dyrdak R; Lee J; Dopico XC; Dosenovic P; Peacock TP; McInerney GM; Albert J; Corcoran M; Bloom JD; Murrell B; Karlsson Hedestam GB; Hällberg BM
Cell Rep Med; 2024 Jun; 5(6):101577. PubMed ID: 38761799
[TBL] [Abstract][Full Text] [Related]
14. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
15. Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera.
Lee J; Naoe Y; Bang U; Nakagama Y; Saito A; Kido Y; Hotta A
Virology; 2024 Jul; 595():110067. PubMed ID: 38653156
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
[TBL] [Abstract][Full Text] [Related]
17. Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain.
Miller NL; Clark T; Raman R; Sasisekharan R
Cell Rep Med; 2022 Feb; 3(2):100527. PubMed ID: 35233548
[TBL] [Abstract][Full Text] [Related]
18. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
19. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Muecksch F; Weisblum Y; Barnes CO; Schmidt F; Schaefer-Babajew D; Wang Z; C Lorenzi JC; Flyak AI; DeLaitsch AT; Huey-Tubman KE; Hou S; Schiffer CA; Gaebler C; Da Silva J; Poston D; Finkin S; Cho A; Cipolla M; Oliveira TY; Millard KG; Ramos V; Gazumyan A; Rutkowska M; Caskey M; Nussenzweig MC; Bjorkman PJ; Hatziioannou T; Bieniasz PD
Immunity; 2021 Aug; 54(8):1853-1868.e7. PubMed ID: 34331873
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
